A study of safety and efficacy of ipragliflozin in the treatment of diabetes in Kanagawa
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000014425
- Lead Sponsor
- The Study Group of the Diabetes Committee, Kanagawa Physicians Association
- Brief Summary
1. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. Kawata T, et al. J Clin Med Res. 2017 Jul; 9(7): 586-595. 2. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study. Iizuka T, et al. J Clin Med Res. 2016 Feb; 8(2): 116-125.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 500
Not provided
1) Has hypersensitivity to ipragliflozin or any other excipient of ipragliflozin 2) With severe ketosis, diabetic coma, or precoma within 6 months 3) With severe infection, pre or post surgery, and serious trauma 4) With severe renal dysfunction 5) Considered as inadequate by the investigator 6) Is pregnant or possibility of pregnant, planning or possibility of pregnant during research (Except for acceptable method of birth control, surgically sterilized, and postmenopause), or nursing
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method